Zobrazeno 1 - 10 of 18 pro vyhledávání: '"Richard A Pollak"'
1
HTX-011 Reduced Pain and Opioid Use After Primary Total Knee Arthroplasty: Results of a Randomized Phase 2b Trial
Autor: Jia Hu, Gwo-Chin Lee, Alexander P. Sah, David Leiman, Richard A. Pollak, Paul F. Lachiewicz
Publikováno v: The Journal of Arthroplasty. 35:2843-2851
HTX-011 is an extended-release, dual-acting local anesthetic consisting of bupivacaine and low-dose meloxicam in a novel polymer that is administered by needle-free application during surgery. The active ingredients are released from the polymer by c
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97c23f54422a64b410b033dad2ed927c
https://doi.org/10.1016/j.arth.2020.05.044
Zobrazit plný text záznamu
2
Mechanism of action of HTX-011: a novel, extended-release, dual-acting local anesthetic formulation for postoperative pain
Autor: Thomas Ottoboni, Eugene R. Viscusi, Richard A Pollak, Barry Quart, Joseph F. Dasta, Jayne Pawasauskas
Publikováno v: Regional Anesthesia & Pain Medicine. 45:117-123
Background and objectives Obtaining consistent efficacy beyond 12–24 hours with local anesthetics, including extended-release formulations, has been a challenging goal. Inflammation resulting from surgery lowers the pH of affected tissues, reducing
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b698614d3968e3f5acd013038e338b7
https://doi.org/10.1136/rapm-2019-100714
Zobrazit plný text záznamu
3
Response to the letter to the editor by Hafer and Johnson concerning ‘Mechanism of action of HTX-011: a novel, extended-release, dual-acting local anesthetic formulation for postoperative pain’
Autor: Thomas Ottoboni, Joseph F. Dasta, Eugene R. Viscusi, Jayne Pawasauskas, Barry Quart, Richard A Pollak
Publikováno v: Regional Anesthesia and Pain Medicine
To the Editor We appreciate the comments provided by Hafer and Johnson[1][1] regarding our recent manuscript.[2][2] Their primary concern appears to be the clinical evidence supporting the analgesic properties of HTX-011 beyond 24 hours. HTX-011 is a
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0608c8f1e3892ea1bb2a02b2a650d2a8
https://doi.org/10.1136/rapm-2020-101488
Zobrazit plný text záznamu
4
Long-Term Follow-up of Onychomycosis Patients Treated With Efinaconazole
Autor: Richard A, Pollak, Carla, Ilie
Publikováno v: Journal of drugs in dermatology : JDD. 16(12)
Onychomycosis is a common disease that remains difficult to treat despite the introduction of new topical agents. Clinical trials on efinaconazole and tavaborole included 48 weeks' daily treatment regimens with a 4-week follow-up. It has been suggest
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::2c501f493382b6e2265421bfb017020d
https://pubmed.ncbi.nlm.nih.gov/29240863
Zobrazit plný text záznamu
5
Access of efinaconazole topical solution, 10%, to the infection site by spreading through the subungual space
Autor: Boni E, Elewski, Richard A, Pollak, Radhakrishnan, Pillai, Jason T, Olin
Publikováno v: Journal of drugs in dermatology : JDD. 13(11)
To evaluate the ability of efinaconazole vehicle to reach the site of toenail onychomycosis by spreading through the subungual space between the nail plate and nail bed. Lacquer-based vehicles are primarily limited to application on the nail plate an
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::abe54c95b4ce1f3d9f51bbe62f9c1594
https://pubmed.ncbi.nlm.nih.gov/25607708
Zobrazit plný text záznamu
6
Efinaconazole topical solution, 10%: the development of a new topical treatment for toenail onychomycosis
Autor: Richard A, Pollak
Publikováno v: Journal of the American Podiatric Medical Association. 104(6)
Toenail onychomycosis is a common disease with limited treatment options; treatment failure and relapse are frequently encountered. Many patients experience long-standing disease affecting multiple toenails, with substantial discomfort and pain. Alth
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::48b2d231d35ff78721eaea097d1902ff
https://pubmed.ncbi.nlm.nih.gov/25514267
Zobrazit plný text záznamu
7
The efficacy and safety of tavaborole, a novel, boron-based pharmaceutical agent: phase 2 studies conducted for the topical treatment of toenail onychomycosis
Autor: Mirna E, Toledo-Bahena, Alicia, Bucko, Jorge, Ocampo-Candiani, Maira E, Herz-Ruelas, Terry M, Jones, Michael T, Jarratt, Richard A, Pollak, Lee T, Zane
Publikováno v: Journal of drugs in dermatology : JDD. 13(9)
To assess the potential efficacy, safety, and optimal dosing concentration of tavaborole, a novel, boron-based pharmaceutical agent with broad-spectrum antifungal activity, for the treatment of onychomycosis of the toenail due to dermatophytes.One do
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::75ead8ee857357483c79190e0c73887a
https://pubmed.ncbi.nlm.nih.gov/25226015
Zobrazit plný text záznamu
10
Studies with hydroxyurea VI. Effects of hydroxyurea on the metabolism of sensitive and resistant strains of Escherichia coli
Autor: Howard S. Carr, Herbert S. Rosenkranz, Richard D. Pollak
Publikováno v: Biochimica et Biophysica Acta (BBA) - Nucleic Acids and Protein Synthesis. 149:228-245
The effects of hydroxyurea on the metabolism of a sensitive and resistant strain of Escherichia coli were investigated. In sensitive bacteria the drug inhibits DNA synthesis and especially the incorporation of adenosine, deoxyadenosine and cytidine i
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b5bc5f2dcada72625c29ffd838c6e68
https://doi.org/10.1016/0005-2787(67)90704-6
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje